Success Metrics

Completion Rate
0%(0/1)
Active Trials
1(17%)
Terminated
1(17%)

Phase Distribution

Ph phase_3
2
33%
Ph phase_1
4
67%

Phase Distribution

4

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
4(66.7%)
Phase 3Large-scale testing
2(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(3)
Terminated(1)
Other(2)

Detailed Status

unknown2
Not yet recruiting2
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (66.7%)
Phase 32 (33.3%)

Trials by Status

recruiting117%
unknown233%
terminated117%
not_yet_recruiting233%

Recent Activity

1 active trials
Showing 5 of 6
recruitingphase_3

IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)

NCT06647862
not_yet_recruitingphase_1

A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid Tumors

NCT07170787
not_yet_recruitingphase_3

A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma

NCT06465446
unknownphase_1

A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

NCT05140811
terminatedphase_1

Exploratory Study of IMM01 for Injection in the Treatment of Refractory or Recurrent Hematologic Malignancy

NCT05860075
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06647862Phase 3

IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)

Recruiting
NCT07170787Phase 1

A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid Tumors

Not Yet Recruiting
NCT06465446Phase 3

A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma

Not Yet Recruiting
NCT05140811Phase 1

A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

Unknown
NCT05860075Phase 1

Exploratory Study of IMM01 for Injection in the Treatment of Refractory or Recurrent Hematologic Malignancy

Terminated
NCT05833984Phase 1

Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas

Unknown

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6